Our objectives were threefold: capture general cytokine response patterns observed in clinical stroke studies, including early TNF-α/IL-6 peaks and delayed IL-10 elevation; to predict the therapeutic effects of IL-10 augmentation and TNF-α inhibition on inflammation resolution; and to identify critical parameters governing transitions between pro- and anti-inflammatory states. The gene discussed is IL10; the disease is stroke disorder.